Mantle Cell Lymphoma

P2, N=41, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting

P2, N=25, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Nov 2025 --> Jul 2027

P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2026 --> May 2027

P2, N=300, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027

This review summarizes emerging strategies, resistance mechanisms, and translational approaches, emphasizing Bruton tyrosine kinase (BTK) inhibitors, CAR T-cell therapy, bispecific antibodies, SOX11-directed therapy, venetoclax regimens, and precision medicine...This review uniquely integrates evidence on resistance biology, SOX11 therapy, CAR T-cell failure mechanisms, and precision strategies. Future studies should prioritize biomarker-driven approaches, CAR T-cell optimization, safer agents, and accessible treatments for refractory cases.

Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.

P2, N=48, Active, not recruiting, University College, London | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Nov 2026 --> Jun 2026

P1, N=15, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> May 2026

In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.

This multitargeted regimen addresses the biologic heterogeneity of MCL and permits flexible MRD-guided decisions on consolidation and maintenance. Trial Registration: ClinicalTrials.gov identifier: NCT04626791.

P1, N=106, Completed, Alliance for Clinical Trials in Oncology | Phase classification: P2 --> P1

P2, N=11, Terminated, University of Washington | N=20 --> 11 | Trial completion date: Jul 2028 --> May 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> May 2026; The trial closed early due to slow accrual.